Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades

Abstract

Objectives: To evaluate the relationship between metabolic syndrome (MetS) and annual prostate growth rates in Chinese patients of different age decades with benign prostatic hyperplasia (BPH). Methods: We retrospectively analyzed the clinical data obtained from 1,052 Chinese men with BPH. Overnight fasting venous blood specimens were collected and serum levels of prostate-specific antigen, fasting blood glucose, high-density lipoprotein cholesterol, total cholesterol and triglyceride were recorded. We divided age into four groups: 50 ≤ age ≤ 60, 60 < age ≤ 70, 70 < age ≤ 80 and 80 < age ≤ 90. Pearson's correlation coefficient was used to test the linearity of the relationships between each of the MetS components and prostate volume and annual prostate growth rates generally and in different age decades. Results: The median total prostate volume (69.01 ml) and median annual prostate growth rate (1.92 ml/year) were significantly higher in the MetS group compared with the non-MetS group (57.26 ml and 1.23 ml/year). Significant positive correlations were also found in total prostate volume and different age decades, while negative correlations were seen in annual prostate growth rate and different age decades. Conclusions: MetS is associated with an increased risk of total volume and annual prostate growth rate in BPH patients of different age decades.

The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome

“…Evidences showed that inflammatory infiltrates are commonly found in BPH lesions [18,19,20], and these inflammatory cells release cytokines and growth factors that can stimulate the proliferation of stroma and epithelial cells, thus contributing to the development and progression of BPH. Recently, it has been shown that patients affected by MetS are at higher risk of BPH/LUTS [3,4,5], suggesting that MetS has very heterogeneous clinical ramifications. Although the exact nature and origins of the associations between MetS and BPH/LUTS are still poorly understood, chronic inflammation has been proposed as a candidate mechanism at the crossroad between these 2 clinical entities [6].…”

“…Metabolic syndrome (MetS) is a clinical condition characterized by the coexistence of multiple cardiovascular risk factors including obesity, dyslipidemia, elevated blood pressure and insulin resistance [2]. Recently, MetS has been considered to play an important role in the development and progression of BPH/LUTS [3,4,5]. Although the exact pathophysiological mechanism between MetS and BPH/LUTS remains unclear, emerging evidence has shown that chronic inflammation is a candidate mechanism at the crossroad between MetS and BPH/LUTS [6,7].…”

Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients

“…1. Finally, 16 studies [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] were included in this meta-analysis. Table 1 summarizes the main characteristics of included studies involving 1895 cases of BHP patients with MetS and 2224 cases of BHP patients without MetS.…”

Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia

“…The etiology of BPH has intrigued researchers in various fields of medicine. Some of them suggested that metabolic syndrome is significantly associated with the development of BPH [3,4]. BPE usually involves the hypertrophy of all elements of prostate.…”